LINC00460 was observed to be significantly elevated in doxorubicin-resistant breast cancer cells, and LINC00460, together with FUS, promotes MYC expression by influencing the efficiency of intron removal during mRNA maturation. Here, LINC00460 is linked to breast carcinoma.